DiaMonTech AG

  • WKN: A255G4
  • ISIN: DE000A255G44
  • Land: Deutschland

Nachricht vom 19.11.2019 | 11:12

DiaMonTech: First-time product presentation of the 'D-Base' at the world-wide largest medical technology trade fair COMPAMED/MEDICA 2019


DGAP-Media / 19.11.2019 / 11:12

DiaMonTech: First-time product presentation of the 'D-Base' at the world-wide largest medical technology trade fair COMPAMED/MEDICA 2019
 

Berlin, 19 November 2019 - The DiaMonTech product 'D-Base', a device for the non-invasive blood glucose measurement, is exhibited for the first time at a trade fair. The partner company seleon GmbH, a leading international medical technology service provider, will present the measuring device at its stand at the COMPAMED/MEDICA 2019 medical technology trade fair. Visitors will have the opportunity to test the device in hall 8b at stand G05 and can thus determine their blood glucose level precisely and completely painlessly within seconds.

"We are pleased to be able to exhibit the 'D-Base' at our stand. It is one of the major innovations at this year's COMPAMED/MEDICA 2019. As a partner of DiaMonTech, we have contributed to the development of this great technology", says Harald Genger, managing director of seleon GmbH. "We perceive this technology as a milestone for millions of diabetics in Germany. Visitors to our stand can familiarise themselves with the new measuring technology."

The 'D-Base' allows non-invasive blood glucose measurement using a laser-based technology and is optimized for use in professional environments (e.g. diabetes centers). The measuring instrument received the CE-certification in March this year. The handling is simple: the user places his finger on a sensor field for a few seconds and the blood glucose level is shown on a display. The blood sugar can thus be measured precisely and painlessly without a drop of blood. The measurement can be made as often as desired without consumables (test strips). The need to prick several times a day is therefore completely omitted.

"The successful use of the 'D-Base' in practice is based on more than 20 years of intensive research and development work. We are working hard to make this technology available to as many diabetes patients as possible as quickly as possible, thereby making their lives easier. For this purpose, we are developing the smaller 'D-Pocket' in the size of a smartphone. We intend to launch this product on the market at the end of next year. It could thus be a constant 'companion' for diabetes patients", says Thorsten Lubinski, Co-founder and CEO of DiaMonTech AG.

About DiaMonTech
DiaMonTech AG is a medical technology company that specializes in the development, design and sale of products for medical diagnostics. The patented photothermal detection technology based on infrared lasers enables the precise measurement of relevant blood parameters. The first application is the non-invasive blood glucose measurement, which enables an accurate and fast measurement without pain.

More information about DiaMonTech can be found at www.DiaMonTech.de/home.

About seleon
seleon GmbH has been developing and producing complex equipment for customers in the medical technology field since 1998, growing into a leading medical technology service provider. We develop individual solutions in partnership with our customers around the world, quickly leading to success. With our team of experienced physicists, engineers, computer scientists, process engineers and consultants, every one of our projects reaffirms our ambition to find innovative solutions and help our customers succeed in the market.

More information about seleon can be found at https://www.seleon.de.

Press Contact
Alexander Neblung
Kirchhoff Consult AG
Phone +49 40 60 91 86 70
E-Mail DiaMonTech@kirchhoff.de



End of Media Release


Issuer: DiaMonTech AG
Key word(s): Research/Technology

19.11.2019 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

MBH Corporation. Hohes Kurspotenzial

Die MBH Corporation plc hat in den vergangenen Berichtsperioden eine sehr hohe M&A-Aktivität aufgezeigt. Unter Anwendung der so genannten Agglomeration Methodology hat die Beteiligungsgesellschaft branchenübergreifend seit 2018 11 Beteiligungen erworben. Bei einem Pro-Forma-Umsatz der Beteiligungsgesellschaften von über 120 Mio. GBP und einem Pro-Forma-EBITDA in Höhe von über 11 Mio. GBP weist die MBH derzeit eine Marktkapitalisierung von umgerechnet gerade einmal 19,8 Mio. GBP auf. Ausgehend vom aktuellen Aktienkurs liegt zu unserem Kursziel in Höhe von 1,95 € ein hohes Kurspotenzial vor

News im Fokus

MTU Aero Engines AG nimmt Jahresprognose für 2020 zurück

26. März 2020, 15:15

Aktueller Webcast

SeaChange Corporation

Fourth Quarter Fiscal Year 2020 Results

06. April 2020

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Kaufen

27. März 2020